MedMira Inc
XTSX:MIR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.075
0.125
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
MedMira Inc
MedMira Inc
Total Equity
MedMira Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
MedMira Inc
XTSX:MIR
|
Total Equity
-CA$16.9m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-10%
|
|
|
Titan Medical Inc
TSX:TMD
|
Total Equity
$2.7m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-21%
|
|
|
Profound Medical Corp
TSX:PRN
|
Total Equity
$39.2m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Opsens Inc
TSX:OPS
|
Total Equity
CA$33.8m
|
CAGR 3-Years
30%
|
CAGR 5-Years
13%
|
CAGR 10-Years
26%
|
|
|
Nanalysis Scientific Corp
XTSX:NSCI
|
Total Equity
CA$23.5m
|
CAGR 3-Years
18%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Total Equity
CA$1.7m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
MedMira Inc
Glance View
MedMira, Inc. is a biotechnology company, which through its subsidiaries, engages in the research, development, manufacture, and commercialization of diagnostics and technology platforms. The company is headquartered in Halifax, Nova Scotia. The firm is engaged in the development and commercialization of rapid diagnostics and technology platforms. The MedMira Rapid Vertical Flow (RVF) Technology platform is the basis for the Company's line of rapid tests. Its technology platform detects multiple biomarkers specific to several diseases using a single cartridge. Its Multiplo line of rapid tests for human immunodeficiency virus (HIV), Hepatitis B and C, and syphilis uses the platforms capabilities to deliver approximately up to four test results using one test cartridge and one drop of specimen. The company also has a research product line that facilitates technology licensing, contract manufacturing, and regulatory consulting. The firm sells its rapid tests through a network of medical distributors and strategic business development partners to customers in all sectors of the healthcare industry, including laboratories, hospitals and point-of-care clinics, among others.
See Also
What is MedMira Inc's Total Equity?
Total Equity
-16.9m
CAD
Based on the financial report for Apr 30, 2024, MedMira Inc's Total Equity amounts to -16.9m CAD.
What is MedMira Inc's Total Equity growth rate?
Total Equity CAGR 10Y
-10%
Over the last year, the Total Equity growth was -20%. The average annual Total Equity growth rates for MedMira Inc have been -3% over the past three years , -5% over the past five years , and -10% over the past ten years .
You don't have any saved screeners yet
